Activation of autophagy inhibits nucleotide ‐binding oligomerization domain‐like receptor protein 3 inflammasome activation and attenuates myocardial ischemia‐reperfusion injury in diabetic rats
ConclusionActivation of autophagy can suppress the formation of NLRP3 inflammasome, which in turn attenuates myocardial ischemia ‐reperfusion injury in diabetic rats.
CONCLUSIONS: The average patient is middle aged (often male) with a history of subacute back pain, sometimes presenting fever and/or neurological damage on diagnosis. Acute phase reactants are frequently raised. Diabetes mellitus, endocarditis and immunosuppressed patients may have the worst chance of a good outcome, therefore these patients should be more carefully managed (always try to obtain an imaging-guided biopsy, correct antibiotic treatment, and a functional and clinical follow-up). PMID: 32446680 [PubMed - as supplied by publisher]
TYPE 2 diabetes does not pose a threat if you keep blood sugar levels under control. Diet acts as the ultimate bulwark against high blood sugar levels and a natural green powder has been proven to lower blood sugar.
Publication date: Available online 24 May 2020Source: Canadian Journal of DiabetesAuthor(s): Jacob M. Zamora, Jason M. Kong
Does the Trump-hyped drug hydroxychloroquine have the potential to treat diabetes?
All about “blood glucose management” for diabetes: how does it work, and how can you master it?
This study, for instance, attributes a patient’s waitlist/transplant outcome to the very last dialysis facility the patient was associated with. In epidemiology speak, this means the causal inference authors are trying to draw between for-profit status and good transplant outcomes is subject to time-varying confounding. As an example, if one is seeking an association between testosterone levels and risk of a heart attack, using the last testosterone level available would be a poor way of doing this study because testosterone levels are known to vary over time. The same applies to dialysis facilities. Patie...
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Kehinde S. Olaniyi, Oluwatobi A. Amusa
Publication date: Available online 24 May 2020Source: PhytomedicineAuthor(s): Nani Wang, Pingcui Xu, Xuping Wang, Weixuan Yao, Binjie Wang, Yuanzhao Wu, Dan Shou
Derek Lowe in his Science Magazine blog asks the obvious question. Why the hell are we still conducting trials of hydroxychloroquine for Covid-19 and why are doctors giving it to people. The verdict is in. It doesn't work. On the contrary, it kills people. He discusses this paper inThe Lancet which is a retrospective observational study -- yes, yes, not a randomized controlled trial but quite compelling:[W]hen compared with mortality in the control group [i.e., people hospitalized with Covid-19 who did not receive HCQ] (9 ·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·223–1&...
This special issue focuses on Inpatient care for People with Diabetes and COVID-19 answering questions from a large online audience as a launching point for discussion. Recorded May 14, 2020 This is a part of the American Diabetes Associations ongoing project providing resources for practicing clinicians on the care of Diabetes during the Covid-19 pandemic. Today’s discussion is an audio version of a webinar recorded on May 14, 2020. Presented by: Boris Draznin, MD, PhD University of Colorado, Denver Carol Levy, MD, CDE Icahn School of Medicine at Mount Sinai Jing Chao, MD University of Washington